• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » Disease categories and therapies » Ocular

Ocular
Ocular RSS Feed RSS

Ocular

Raytone Biotechnology discovers new compounds to treat cataracts and presbyopia

May 10, 2024
Raytone Biotechnology Co. Ltd. has described compounds based on oxidative stress and antiamyloid aggregations reported to be useful for the treatment of cataracts and presbyopia.
Read More
Eye and DNA
Ocular

Preclinical safety and efficacy of intein-based dual-AAV gene therapy for Stargardt disease

May 10, 2024
At the recently concluded ARVO meeting, Splicebio S.L. presented the first preclinical results on the company’s new candidate, SB-007, for the treatment of Stargardt disease, a rare genetic disease caused by mutations in the ABCA4 gene with no approved treatment on the market.
Read More
Eye wireframe illustration
Ocular

Therini Bio’s THN-391 shows efficacy in rodent models of ocular diseases

May 10, 2024
Vascular dysfunction that causes leakage of plasma proteins such as fibrinogen, fibrin deposits and innate immune cell activation is the cause of neurodegenerative ocular diseases, including diabetic macular edema, age-related macular degeneration or diabetic retinopathy.
Read More
Vial and syringe with DNA
Ocular

ASGCT: ‘From darkness to light’ in ocular gene therapy

May 10, 2024
By Mar de Miguel
From glaucoma to Stargardt disease, age-related macular degeneration (AMD) to retinitis pigmentosa, or a corneal transplant to Bietti’s crystalline dystrophy, the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) is working to bring some light to patients with age and congenital diseases that affect vision. From May 7-11, 2024, thousands of scientists are gathering in Baltimore to show their advances against the challenges of delivering genes and cells to the correct place, avoiding immunogenicity and improving diseases.
Read More
Close-up of elderly eye
Biomarkers

Genetic variation in METTL23 gene tied to normotensive glaucoma

May 9, 2024
Recent findings discovered a mutation in the METTL23 gene, which encodes methyltransferase-like protein 23, in a pedigree of normal-tension glaucoma (NTG). The aim of researchers from the Institute for Vision Research, The University of Iowa Roy J and Lucille A Carver College of Medicine was to confirm an association of mutations in this gene with NTG.
Read More
Ocular

CREB-activating P1-CPP induces retinal ganglion cell survival in glaucoma model

May 8, 2024
Previous findings had shown that injecting pepatin-1 prevented the death of retinal ganglion cells (RGCs) in rats with ocular hypertension. Additionally, transcriptomic analysis in RGCs revealed cAMP response element-binding protein (CREB) signaling to be activated by peptain-1 conjugated with a cell-penetrating peptide, named P1-CPP.
Read More

Eyepoint tunes into NPDR; Duravyu signal weak in phase II

May 6, 2024
By Randy Osborne
Not long after Ocular Therapeutix Inc. unveiled positive phase I data in non-proliferative diabetic retinopathy with Axpaxli (axitinib intravitreal implant), Eyepoint Pharmaceuticals Inc. offered less-sunny phase II data from the Pavia trial testing Duravyu (vorolanib intravitreal insert), previously known as EYP-1901, in the same indication.
Read More
Ocular

Soluble Fas ligand prevents disease progression in glaucoma model

May 6, 2024
Schepens Eye Research Institute presented new preclinical data on its AAV2.sFasL gene therapy, an adeno-associated virus (AVV2) encoding soluble Fas ligand (sFasL) for the potential prevention of glaucoma.
Read More
Ocular

FDA accepts IND for Eluminex’s EB-105

May 2, 2024
Eluminex Biosciences Ltd. announced the FDA’s acceptance of their IND application for EB-105, a trispecific fusion antibody targeting vascular endothelial growth factor A (VEGF-A, and isomers), VEGF-B, placental growth factor (PlGF), angiopoietin-2 (Ang-2) and interleukin-6 receptor (IL-6R) for the treatment of diabetic macular edema (DME).
Read More
Ocular

cGAS inhibitors described in Bellbrook Labs patent

April 30, 2024
Work at Bellbrook Labs LLC has led to the discovery of imidazolyl-alkoxyquinolin-2-amines acting as cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors.
Read More
Previous 1 2 … 12 13 14 15 16 17 18 19 20 … 388 389 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • 3D heart in chest

    At CRVBC 2025: Aging is circulating in your blood

    BioWorld Science
    All kinds of substances circulate through the bloodstream. Some are beneficial, like oxygen or nutrients, and others less so, like waste products, toxins,...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe